Illumina, Inc. (ILMN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$290.06+0.44%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put ILMN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Operating margin near 23.4% in 2026: Operating margin: 21.14%.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look high — the market is pricing in about 55% growth a year, above the roughly 8% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskILMN’s growth case rests on durable revenue gains, earnings improvement, and stronger operating margins. Revenue growth slowed to 4.2% year over year in Q3 FY2026, despite an EPS beat. The market prices ILMN at 53× P/E versus a 37× peer median and its 39× historical multiple. Expectations look full, with more growth priced in than our forecast. The risk is operating margin pressure: 21.14% in 2026 versus a near-23.4% primary-pillar level. Our model puts the next-quarter miss probability near 17%. Peer multiples imply a price about 55% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. ILMN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering ILMN (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for ILMN in the last 4 months.
Continue this research
Compare ILMN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ILMN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put ILMN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Raise revenue and earnings while improving operating margins
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $290.06
The last 12 months of price, then the range of analyst 12-month targets from today’s $290.06.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Raised revenue outlook and strong EPS guidance support growth and earnings objectives.
Reported growth concerns temper the strong beat and raise questions about sustaining performance.
Earnings beat is offset by after-hours share decline, signaling concerns about outlook or results quality.
Reported China-related pressure and a sharp selloff signal a potential growth headwind.
Legal issues could hinder operational and financial objectives.
Upgrade to Buy supports positive outlook on Illumina's performance.
Advances: Integrate SomaLogic acquisition and expand multiomics portfolio
Collaboration could enhance multiomics portfolio and growth.
Director's sale raises concerns about leadership stability.
